Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA

Completed

Conditions studied: Microdeletion Syndromes, Trisomy 21, Trisomy 18, Trisomy 13, Sex Chromosome Abnormalities

In brief

The purpose of this study is to collect blood from families with a child who has been diagnosed with a chromosomal disorder including microdeletions in order to further develop a non-invasive prenatal screening test based on fetal DNA isolated from maternal blood.

Key facts

Study ID

NCT02109770

Run by

Natera, Inc.

People needed

216

Starts

2012-10-01

Expected to finish

2019-08-01

Last updated by the study team

2019-08-26

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Couples who have a child diagnosed with an autosomal chromosome abnormality (e.g. Down syndrome, Edwards syndrome, Patau syndrome).
• Couples who have a child diagnosed with a sex chromosome abnormality (e.g. Turner syndrome, Klinefelter syndrome, Triple X syndrome, 47, XYY).
• Couples who have a child diagnosed with a microdeletion/duplication syndrome (a positive microarray test).

You may not qualify if…

• Not an English language or Spanish language speaker
• Genetics report is not available

Where it is running

• Natera — San Carlos, California, United States
• Children's Hospital Of Philadelphia — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.